fingolimod sandoz 0.25 mg capsule
sandoz pharmaceuticals ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika
fingolimod-mepha 0,25 mg capsule
mepha pharma ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika
fingolimod-mepha 0,5 mg capsule
mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika
tysabri 150 mg/ml injektionslösung in einer fertigspritze
biogen switzerland ag - natalizumabum - injektionslösung in einer fertigspritze - natalizumabum 150 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.45 mg. - multiple sklerose - biotechnologika
fingolimod accord 0.5 mg capsule rigide
accord healthcare ag - fingolimodum - capsule rigide - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), aqua, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, e 172 (flavum), pro capsula. - multiple sklerose - synthetika
fingolimod devatis 0.25 mg capsule
devatis ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, carmellosum calcicum, natrii stearylis fumaras corresp. natrium 0.0295 mg, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), alcohol butylicus, aqua purificata, propylenglycolum, ethanolum, alcohol isopropylicus, ammoniae solutio 28 per centum, pro capsula. - multiple sklerose - synthetika
fingolimod devatis 0.5 mg capsule
devatis ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, carmellosum calcicum, natrii stearylis fumaras corresp. natrium 0.0295 mg, kapselhülle: gelatina, e 171, e 102 0.0283 mg, e 110 0.0033 mg, drucktinte: lacca, e 172 (nigrum), alcohol butylicus, aqua purificata, propylenglycolum, ethanolum, alcohol isopropylicus, ammoniae solutio 28 per centum, pro capsula. - multiple sklerose - synthetika
dimethyl fumarate mylan
mylan ireland limited - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.